Incyte won't move ahead with phase 3 trial of ovarian cancer asset
FROM THE WIRE · SEEKINGALPHA.COM
Incyte stops plans for a phase 3 ovarian cancer trial of INCB123667 with Avastin, citing portfolio priorities. Read more here.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralThe decision reflects portfolio priorities and may matter for the biotech stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Incyte halts the phase 3 plan for INCB123667 with Avastin.
- 02The decision cites portfolio priorities.
- 03The company says it does not affect financial guidance.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets